Compare T1 Energy Inc. Common Stock (TE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T1 Energy Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? T1 Energy Inc. Common Stock trades at $2.81 (market cap $946.42M), while State Street SPDR S&P Biotech ETF trades at $147.08 (market cap $10.27B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 10.9× T1 Energy Inc. Common Stock's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, T1 Energy Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T1 Energy Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| TE | XBI | |
|---|---|---|
Market Cap | $946.42M | $10.27B |
Volume | 12,898,774 | 9,751,587 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $12.04 | $169.55 |
52-Week Low | $2.72 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $1.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
T1 Energy (TE) trades at $3.16, down 1.56% today, reflecting ongoing investor caution despite a mixed earnings history. The company shows significant revenue growth from $755M in 2025 to $997M in 2026 but remains deeply unprofitable with a -38.49% net margin. Recent news highlights strategic moves toward vertical integration in solar manufacturing and energy storage, including the G2_Austin facility development and new supply agreements, which are central to its growth narrative.
The investment case hinges on execution of vertical integration and policy tailwinds, offering substantial upside to the $8 consensus target, but high execution risk, persistent losses, and regulatory scrutiny present clear dangers. Analyst sentiment is mixed with a Moderate Buy rating, yet the stock's viability depends heavily on future profitability improvements from 2027 onward.
XBI trades at $146.8, down 3.04% today, with a bearish technical signal driven by selling pressure in moving averages. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than diversified healthcare funds.
Outlook remains mixed with neutral analyst consensus but positive sector catalysts. Opportunities include biotech innovation and M&A potential, while risks involve high volatility, regulatory uncertainty, and expense ratios above broader healthcare ETFs. Investors should weigh targeted biotech exposure against sector-wide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T1 Energy Inc. Common Stock
T1 Energy Inc. manufactures photovoltaic solar modules and cells in US, operating a solar manufacturing facility in Texas acquired from Trina Solar. The company was formerly known as FREYR Battery before rebranding as T1 Energy in 2025 and changing its NYSE ticker from FREY to TE.
Read more on TE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
